Literature DB >> 17222788

Tracking normalization of brain tumor vasculature by magnetic imaging and proangiogenic biomarkers.

Adília Hormigo1, Philip H Gutin, Shahin Rafii.   

Abstract

Clinical assessment of the response to antiangiogenic therapy has been cumbersome. A study in this issue of Cancer Cell demonstrates that a combination of magnetic resonance imaging (MRI) for quantification of normalized vessels with measurements of circulating levels of proangiogenic factors, including FGF2, SDF1, and viable circulating endothelial cells, provides an effective means to evaluate the response of recurrent glioblastoma to a prototypical pan-VEGF receptor tyrosine kinase inhibitor, AZD2171.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17222788      PMCID: PMC2952447          DOI: 10.1016/j.ccr.2006.12.008

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  13 in total

1.  MR-derived cerebral blood volume maps: issues regarding histological validation and assessment of tumor angiogenesis.

Authors:  A P Pathak; K M Schmainda; B D Ward; J R Linderman; K J Rebro; A S Greene
Journal:  Magn Reson Med       Date:  2001-10       Impact factor: 4.668

Review 2.  Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration.

Authors:  Shahin Rafii; David Lyden
Journal:  Nat Med       Date:  2003-06       Impact factor: 53.440

3.  A physiologic imaging pilot study of breast cancer treated with AZD2171.

Authors:  Kathy D Miller; Michael Miller; Sanjana Mehrotra; Beamon Agarwal; Bruce H Mock; Qi-Huang Zheng; Sunil Badve; Gary D Hutchins; George W Sledge
Journal:  Clin Cancer Res       Date:  2006-01-01       Impact factor: 12.531

4.  NMR imaging of changes in vascular morphology due to tumor angiogenesis.

Authors:  J Dennie; J B Mandeville; J L Boxerman; S D Packard; B R Rosen; R M Weisskoff
Journal:  Magn Reson Med       Date:  1998-12       Impact factor: 4.668

5.  Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Authors:  Ingo K Mellinghoff; Maria Y Wang; Igor Vivanco; Daphne A Haas-Kogan; Shaojun Zhu; Ederlyn Q Dia; Kan V Lu; Koji Yoshimoto; Julie H Y Huang; Dennis J Chute; Bridget L Riggs; Steve Horvath; Linda M Liau; Webster K Cavenee; P Nagesh Rao; Rameen Beroukhim; Timothy C Peck; Jeffrey C Lee; William R Sellers; David Stokoe; Michael Prados; Timothy F Cloughesy; Charles L Sawyers; Paul S Mischel
Journal:  N Engl J Med       Date:  2005-11-10       Impact factor: 91.245

Review 6.  Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.

Authors:  Rakesh K Jain
Journal:  Science       Date:  2005-01-07       Impact factor: 47.728

7.  Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.

Authors:  Frank Winkler; Sergey V Kozin; Ricky T Tong; Sung-Suk Chae; Michael F Booth; Igor Garkavtsev; Lei Xu; Daniel J Hicklin; Dai Fukumura; Emmanuelle di Tomaso; Lance L Munn; Rakesh K Jain
Journal:  Cancer Cell       Date:  2004-12       Impact factor: 31.743

8.  AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.

Authors:  Stephen R Wedge; Jane Kendrew; Laurent F Hennequin; Paula J Valentine; Simon T Barry; Sandra R Brave; Neil R Smith; Neil H James; Michael Dukes; Jon O Curwen; Rosemary Chester; Janet A Jackson; Sarah J Boffey; Lyndsey L Kilburn; Sharon Barnett; Graham H P Richmond; Peter F Wadsworth; Mike Walker; Alison L Bigley; Sian T Taylor; Lee Cooper; Sarah Beck; Juliane M Jürgensmeier; Donald J Ogilvie
Journal:  Cancer Res       Date:  2005-05-15       Impact factor: 12.701

9.  MGMT gene silencing and benefit from temozolomide in glioblastoma.

Authors:  Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

Review 10.  Perfusion MR imaging: basic principles and clinical applications.

Authors:  Soonmee Cha
Journal:  Magn Reson Imaging Clin N Am       Date:  2003-08       Impact factor: 2.266

View more
  18 in total

Review 1.  Mesenchymal stem cells engineered for cancer therapy.

Authors:  Khalid Shah
Journal:  Adv Drug Deliv Rev       Date:  2011-06-29       Impact factor: 15.470

2.  Avastin® in combination with gemcitabine and cisplatin significantly inhibits tumor angiogenesis and increases the survival rate of human A549 tumor-bearing mice.

Authors:  Ying Liu; Xizheng Xia; Mingkai Zhou; Xiaojun Liu
Journal:  Exp Ther Med       Date:  2015-04-01       Impact factor: 2.447

3.  Cancer cell glycocalyx mediates mechanotransduction and flow-regulated invasion.

Authors:  Henry Qazi; Rocio Palomino; Zhong-Dong Shi; Lance L Munn; John M Tarbell
Journal:  Integr Biol (Camb)       Date:  2013-09-30       Impact factor: 2.192

Review 4.  Progress in tumor vascular normalization for anticancer therapy: challenges and perspectives.

Authors:  Bingxue Shang; Zhifei Cao; Quansheng Zhou
Journal:  Front Med       Date:  2012-03-31       Impact factor: 4.592

5.  Isolated diffusion restriction precedes the development of enhancing tumor in a subset of patients with glioblastoma.

Authors:  A Gupta; R J Young; A I Holodny; A B Lassman; S Karimi; S Sood; Z Zhang; Q Mo; P H Gutin
Journal:  AJNR Am J Neuroradiol       Date:  2011-05-19       Impact factor: 3.825

6.  Dll4 activation of Notch signaling reduces tumor vascularity and inhibits tumor growth.

Authors:  Marta Segarra; Cassin Kimmel Williams; Maria de la Luz Sierra; Marcelino Bernardo; Peter J McCormick; Dragan Maric; Celeste Regino; Peter Choyke; Giovanna Tosato
Journal:  Blood       Date:  2008-06-24       Impact factor: 22.113

7.  Vascular endothelial growth factor-dependent spatiotemporal dual roles of placental growth factor in modulation of angiogenesis and tumor growth.

Authors:  Xiaojuan Yang; Yin Zhang; Yunlong Yang; Sharon Lim; Ziquan Cao; Janusz Rak; Yihai Cao
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-05       Impact factor: 11.205

Review 8.  Imaging hemodynamics.

Authors:  Dominique Jennings; Natarajan Raghunand; Robert J Gillies
Journal:  Cancer Metastasis Rev       Date:  2008-12       Impact factor: 9.264

Review 9.  Stem cell-based therapies for tumors in the brain: are we there yet?

Authors:  Khalid Shah
Journal:  Neuro Oncol       Date:  2016-06-09       Impact factor: 12.300

10.  Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial.

Authors:  Dow-Mu Koh; Matthew Blackledge; David J Collins; Anwar R Padhani; Toni Wallace; Benjamin Wilton; N Jane Taylor; J James Stirling; Rajesh Sinha; Pat Walicke; Martin O Leach; Ian Judson; Paul Nathan
Journal:  Eur Radiol       Date:  2009-06-23       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.